| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.9 | 2.1 |
| Profit before tax | -94.9 | -110.8 |
| Net income | -94.9 | -110.8 |
| EPS (diluted, $ a share) | $-0.73 | $-1.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.7% |
|---|
10-Q filed with the SEC, NASDAQ: ALMS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alumis Inc.: key numbers
- Share price
- $5.14Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alumis Inc.
All →Alumis Financial Results
Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.
- Term
- Q3 2026
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”
Martin Babler, President and Chief Executive Officer of Alumis